roles in cancer therapy, the known antitumor drugs such as DNAsynthesis inhibitors or microtuble modulators are poorly active against solid tumors in the clinic. Thus, in addition to conventional screening efforts, new approaches to the treatment of cancer have been made with the hope of developing an antitumor drug with a different mode of action. Recent progress in cancer research is noteworthy, resulting in an understanding of manysteps of oncogenesis at the molecular level. The transcriptional regulation of genes is the final event conferred by various growth signals and controlled by the modification of chromatin structure and activated transcription factors. The important events in tumor cell growth such as cell cycle transition, production of growth factors or cell death are primarily controlled by transcriptional regulation1'2*.
Thus, the modulation of transcription is expected to becomea newtarget to develop useful drugs against tumor cells which have impaired transcriptional regulation systems consisting of nuclear oncogene and tumor suppressor gene products.
We found that Pseudomonas sp. No. 2663 produced novel antitumor substances, FR901463, FR901464 and FR901465, which possess unique activation ability on SV40 promoter-dependent cellular transcription and potent cytotoxic effect against various humantumor cell Hnes3 '4) .
In this report, we describe the antitumor effects of FR901463, FR901464 and FR901465 against various murine and humanstandard tumors implanted in mice, and possible involvement of transcriptional regulation as the mechanism of FR901464. FR901463, FR901464 and FR901465 were prepared in our Research Laboratories; their chemical structure are shown in Fig. 1 . ADRwas purchased from Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan. Camptothecin was purchased from Sigma chemical Co. Taxol was purchased from WAKO Pure Chemical Industries, Ltd., were dissolved in and diluted with 10%polyoxyethylated (60mol) hydrogenated castor oil in saline (HCO60 solution). The other drugs were dissolved in and diluted with saline. The solutions were given ip or iv to mice at a volume of 10ml/kg body weight. In the in vitro culture test, all the drugs were dissolved in methanol and diluted with the culture medium described below. Animals Female mice of BALB/c, BDFj (C57BL/6 x DBA/2), DBA/2 and C57BL/6 strains were purchased from Charles River Japan Inc., Atsugi, Japan. Female mice of BALB/cnu/nu strain were purchased from CLEA Japan Inc., Tokyo, Japan. Mean tumor weight (C) /
Materials and Methods

Drugs
In the experiment on human solid tumor A549, a 2-week subrenal capsule (SRC) assay by using the immunosuppressive agent FK-506 which was developed in our Research Laboratories was employed5'6). The method of implanting tumors under kidney capsule of the mouse was described by Bogden et al.7'8) .
A 1-mm3 tumor fragments were implanted under kidney capsule of BDFXmice on Day 0 and on Day 14 mice were sacrificed, the tumor bearing kidney was exteriorized and the final size of the implanted tumor was measured as described above. FK-506 (32mg/kg) was injected sc on Day 1, 2, 5, 7, 9 and 12 which completely inhibited the immuneresponse for rejecting the xenograft. Drug efficacy was calculated by the same equation as murine solid tumors (as described above).
Activity Criteria
The criteria for activity and toxicity in in vivo tumor model were estimated according to a modification of the method used by the National Cancer Institute9^We used two criteria as described in each Cell Death Analysis M-8 cells were seeded as described above and incubated in the presence or absence of lOng/ml of FR901464for the various times. Cells were collected, lyzed and the enrichment of mono-and oligonucleosomes in cytoplasm of treated cells was measured by the photometric enzyme immunoassay using Cell Death Detection ELISA (Boehringer Mannheim GmbH) according to the manufacturer's instructions.
Analyses of Endogenous Gene Expression M-8 cells were seeded as described above and treated with or without lOng/ml of FR901464 for 16 hours. Cells were collected by the cell scraper and total RNA was purified by RNeasy Total RNA kit (QIAGEN GmbH) according to the manufacturer's instructions.
RNAconcentrations were determined by using GeneQuant RNA/DNA Calculator (Pharmacia Biotech).
Equal amounts of RNAof each sample were subjected to DEC. 1996 RT-PCR amplification using RNAPCR Kit (TaKaRa) and DNAThermal Cycler 480 (PERKIN ELMER) according to the manufacturer's instructions. Primers used for CDNA amplification of endogenous genes were as follows:
primers for CAT primers for humanc-myc 5 -primer 5 -TACCCTCTCAACGACAGCAGCTCGCCC-AACTCCT-3' 3 -primer 5 -TCTTGACATTCTCCTCGGTGTCCGAGG- primers for human E2F-1 primers for humanp53 3 -primer 5 -CTCATTCAGCTCTCGGAACATCTCGAA- primers for human ciplx)
primers for human /?-actin
primers for human G3PDH 5 -primer 5 -TGAAGGTCGGAGTCAACGGATTTGGTy 3 -primer 5 -CATGTGGGCCATGAGGTCCACCAC-3'
Primers for c-myc, p53, jS-actin and G3PDHwere purchased from CLONTECH Laboratories, Inc. Amplification of CDNAwas carried out for 25 cycles (following the profile of 94°C for 1 minute, 60°C for 1 minute, 72°C for 2 minute), yielding a 494bp, 479bp, 307bp, 371 bp, 523bp, 838bp and 983bp PCR product for CAT, c-myc, E2F, p53, cip-1, jS-actin and G3PDH, respectively. After amplification, amplified DNAwas electrophoresed on 2% agarose gel and stained with ethidium bromide for analysis.
Results
Antitumor Activity against Mouse Ascitic Tumors
The antitumor activities of FR901463, FR901464 and FR901465 against mouse ascitic P388 were examined. The tumor cells were inoculated ip in mice on Day 0. The drugs were given ip to mice once a day for 4 days (Days 1~4). As shown in Table 1 , the three FR compounds prolonged the life span of tumor bearing mice, although FR901465 was less active than FR901463 and FR901464. The effective dose ranges of FR901463 and FR901464 are 1.0 to 3.2mg/kg and 0.056 to 0.18mg/kg, respectively. Tox, a T/C value of <86% indicates toxicity.
Antitumor Effect on HumanSolid Tumor in SRC Assay
The antitumor effects of FR901463 and FR901464 were examined in the SRC assay against human lung adenocarcinoma A549. The 2-week SRC assay by using the immunosuppressive agent FK-506 was employed.
A549 was implanted at Day 0 under kidney capsule of the mouse. The drug was given ip 3 times at 4-days intervals, and the tumors were weighed on exteriorized kidneys. FK-506 was injected sc to inhibit the immune response rejecting the xenograft. As shown in Table  2 Tox, a survival rate of < 65%on evaluation day indicates toxicity. Tox, a survival rate of < 65% on evaluation day indicates toxicity.
Kinetics of Transcriptional Activation Induced by FR901464
M-8 cells, which harbored the SV40 promoter-driven CAT reporter gene, were employed to measure the activities on cellular transcription. FR901464 has a profound enhancing effect on cellular transcription in M-8 cells3). To address whether transcriptional activa- DEC. 1996 On the other hand, in M-8 cell treated with FR901464, a significant decrease in cells entering S phase and exiting from G2/M phase were observed ( Fig. 3B and 3C ). This result indicates that FR901464 induces Gt and G2/M phase arrest in the treated cells. This was also denned by the effect of FR901464 on cell cycle transition of M-8cells after release from serum starvation. As shown in Fig. 4, in starved M-8 Analysis of Cell Death Induced by FR901464 FR901464 has a potent cytotoxic effect on M-8 cells, accompanied by a striking cell shrinkage which is frequently observed in cells with induced DNA fragmentation. To verify whether transcriptional activation induced by FR901464 is implicated in this characteristic cell death, chromatin status in the FR901464-treated cells was examined.Chromatinstatus was evaluated by quantifying the mono-and oligonucleosomes level in the cytoplasm using the photometric enzymeimmunoassay.
As expected, an enrichment of nucleosomes in the cytoplasm of FR901464-treated M-8 cells was observed, suggesting that internucleosomal breakdown of chromatin was induced (Fig. 6) . Moreover, kinetic analysis verified that DNAfragmentation was occurring within 12 hours posttreatment and continued for up to 24 hours, with increasing intensity. of antitumor drug. We therefore examined the antitumor activities of FR901463, FR901464 and FR90146f against several mouse and human tumor cells and investigated the mechanism of action of FR901464. As shown in Tables 1 and 2, FR901463, FR901464 and FR901465 prolonged the life of mice bearing ascitic tumors. In addition, FR901463 and FR901464 exhibited antitumor effects in the SRC assay using human solid tumor A549. In these assay systems, FR901464 showed the most prominent effects amongthe three compounds. Thus, we decided to select FR901464 as a promising candidate compound, and investigated further its antitumor effect against the murine solid tumors and mechanism of action. As expected, FR901464 also inhibited the growth of the murine tumors, Colon 38 and Meth A ( Therefore, cells containing mutated DNAor disordered chromatin structure fail to proceed the cell cycle beyond the Gx or G2/Mphase in which the check systems of the genome function1 7). Thus, it was demonstrated above that FR901464 enhanced transcription, arrested the cell cycle transition in Gx and G2/Mphases and induced internucleosomal DNA fragmentation, and also shown that these biological events occurred with almost the same kinetics, suggesting these are triggered by a commoneffect. In addition, FR901464 was verified to be a transcriptional suppressor rather than activator against inducible genes which may require a strict regulation of displacement and repositioning of nucleosomes for transcriptional activation.
Taken together, these results strongly suggest that the first action of FR901464 in treated cells may be to disrupt the chromatin structure by an unknownmechanism and produce "biologically active chromatins", leading to the transcriptional activation of the integrated virus promoter but suppression of endogenous inducible genes, internucleosomal DNA fragmentation digested by endogenous nucleases and cell cycle arrest at check points, as mentioned above. This is also supported by the fact that a part of FR901464action can be replaced with that of trichostain A, which is a potent inhibitor for histone deacetylase15'18~19).
Although further experiments are necessary to verify the target protein of FR901464, the effort will certainly contribute to the screening for new types of arititumor drugs.
